Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 20,318,411	$ 19,174,061
Marketable securities	0	7,080,053
Accounts receivable trade, net of allowance for doubtful accounts of $0 and $385,362 respectively	2,566,101	3,111,274
Deferred costs	2,911,743	2,566,989
Prepaids and other current assets	3,476,177	4,349,167
Total current assets	29,272,432	36,281,544
Property, plant and equipment, net	17,064,900	15,960,731
Goodwill	7,013,315	25,209,336
Intangible assets, net	2,877,880	47,560,406
Other assets	976,768	1,263,375
Total assets	57,205,295	126,275,392
Current Liabilities
Accounts payable	4,107,388	5,661,173
Accrued liabilities	6,198,488	4,322,901
Long-term debt, current	4,171,456	1,109,612
Notes payable	1,192,666	816,776
Unearned revenues	5,345,225	4,334,120
Total current liabilities	21,015,223	16,244,582
Deferred income taxes	932,662	18,176,190
Notes payable	583,041	825,897
Long term debt	10,828,544	13,890,388
Acquisition-related contingent consideration	0	18,260,000
Other long-term liabilities	562,001	804,546
Total liabilities	$ 33,921,471	$ 68,201,603
Commitments and Contingencies
Stockholders' Equity
Preferred stock; authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 1 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at December 31, 2015 and December 31, 2014	$ 100	$ 100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 56,733,012 and 36,783,857 shares, at December 31, 2015 and December 31, 2014, respectively	56,733	36,784
Additional paid-in capital	396,496,341	350,428,903
Treasury stock, at cost; 110,799 shares at December 31, 2015, and 109,989 shares at December 31, 2014	(707,637)	(705,742)
Accumulated deficit	(372,132,490)	(291,246,538)
Accumulated other comprehensive income	486	1,329
Total Caladrius Biosciences, Inc. stockholders' equity	23,713,533	58,514,836
Noncontrolling interests	(429,709)	(441,047)
Total equity	23,283,824	58,073,789
Liabilities and Equity, Total	$ 57,205,295	$ 126,275,392

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5